02 - ŞEMA TERAPİ' NİN GELİŞİMİ

Summary

This transcript discusses the speaker's journey through psychotherapy training, starting with psychiatry and transitioning to cognitive-behavioral therapy (CBT) and schema therapy. The speaker emphasizes schema therapy's integrative approach, which blends techniques from different schools of therapy. A study comparing schema therapy with transference-focused psychotherapy for treating Borderline Personality Disorder (BPD) reveals that schema therapy is more effective, with higher recovery rates and lower dropout rates. The findings suggest that schema therapy offers a more promising treatment for personality disorders, particularly BPD, than traditional therapies.

Takeaways

• 😀 The speaker embarked on a long journey of 10 years to become a psychotherapist, beginning with psychiatry and moving through various therapeutic models like cognitive behavioral therapy (CBT) and psychoanalysis.
• 😀 The speaker's interest eventually shifted from traditional psychoanalysis to more data-driven therapy techniques like CBT and schema therapy.
• 😀 Schema therapy, developed by Jeffrey Young in the early 1980s, focuses on treating personality disorders, unlike traditional CBT, which primarily addresses issues like depression and panic disorders.
• 😀 Schema therapy is not eclectic; it is an integrative approach that combines techniques from multiple therapeutic schools under one model, aiming for a unified, comprehensive treatment approach.
• 😀 The speaker emphasized the importance of schema therapy as a pioneering model, noting that it integrates cognitive, behavioral, and experiential techniques.
• 😀 Schema therapy is considered superior to traditional approaches like transfer-focused psychotherapy in treating borderline personality disorder (BPD), as demonstrated in clinical studies.
• 😀 In a 2005-2006 study involving 89 patients with borderline personality disorder, schema therapy showed significantly better results compared to transfer-focused psychotherapy in terms of treatment dropout rates.
• 😀 After one year of treatment, the dropout rate for schema therapy was only 7%, compared to 31% for transfer-focused psychotherapy. After three years, schema therapy’s dropout rate remained lower than that of transfer-focused therapy.
• 😀 The study also revealed that schema therapy led to higher rates of complete recovery (45%) compared to transfer-focused psychotherapy (25%).
• 😀 Clinical improvement was more pronounced in schema therapy, with 66% of participants showing significant life improvements, compared to 42% in the transfer-focused psychotherapy group.
• 😀 Overall, while both therapies demonstrated clinical improvement, schema therapy was found to be more effective, especially in treating borderline personality disorder, which had previously been largely unaddressed by other models.

Q & A

What was the therapist's initial path before discovering schema therapy?

The therapist initially chose a long and challenging path, spending about 10 years in psychiatry, before engaging in master's programs and eventually working with cognitive behavioral therapy (CBT), psychoanalysis, and psychodrama.

Why did the therapist shift from psychoanalysis to cognitive behavioral therapy (CBT)?

The therapist found CBT more appealing due to its data-driven and tangible techniques, which were more concrete and practical compared to the more emotional and exploratory work in psychoanalysis.

What made the therapist eventually turn to schema therapy?

After working with cognitive behavioral therapy and psychodrama, the therapist was introduced to schema therapy, which provided a more integrated approach to therapy, blending different techniques and offering a stronger focus on core emotional issues.

What distinguishes schema therapy from other therapeutic models?

Schema therapy is not eclectic but integrative, meaning it combines elements of various therapies (e.g., psychoanalysis, CBT, experiential techniques) under one cohesive model, designed to treat deeply ingrained emotional patterns, particularly in personality disorders.

What was the key finding of the Dutch study comparing schema therapy to transference-focused psychotherapy for borderline personality disorder?

The study found that schema therapy had a significantly lower dropout rate and led to better outcomes in terms of complete recovery (45%) and clinical improvement (66%) compared to transference-focused psychotherapy.

What were the dropout rates in the study for schema therapy versus transference-focused psychotherapy?

In the first year, the dropout rate for schema therapy was 7%, while for transference-focused psychotherapy, it was 31%. In the third year, schema therapy's dropout rate increased to 11%, while transference-focused psychotherapy's rate was 5%.

How did the researchers explain the drop in dropout rates over the course of the study?

The drop in dropout rates was explained by the fact that patients who dropped out had already shown significant improvement, and the remaining participants had little to no further need for treatment.

What does the study suggest about the effectiveness of schema therapy compared to traditional treatments for borderline personality disorder?

The study suggests that schema therapy is more effective than traditional treatments, such as transference-focused psychotherapy, particularly for borderline personality disorder, as it leads to better long-term clinical improvements and recovery.

Why is schema therapy considered a promising approach for treating personality disorders?

Schema therapy is seen as promising because it integrates multiple therapeutic techniques and addresses deeper emotional patterns, especially those related to early life experiences, which are often overlooked in other therapeutic models.

What role did Jeffrey Young play in the development of schema therapy?

Jeffrey Young is credited with developing schema therapy in the early 1980s as a treatment for personality disorders, specifically because existing CBT models were found inadequate for addressing deep-rooted emotional issues in patients.